









Markets
/
Stocks
/
nasdaq-codx
/

Co-Diagnostics Inc

CODX

2.360USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

113.62MMarket Cap

LossP/E TTM



Co-Diagnostics Inc

2.360

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Co-Diagnostics Inc

Currency: USD Updated: 2026-01-13

Key Insights

Co-Diagnostics Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 120 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.50.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Co-Diagnostics Inc's Score

Industry at a Glance

Industry Ranking

120 / 208

Overall Ranking

308 / 4563

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Co-Diagnostics Inc Highlights

StrengthsRisks

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.92M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.92M.

Undervalued

The company’s latest PE is -2.42, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 375.84K shares, increasing 21.57% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 28.92K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 10.46.

Analyst Rating

Based on 2 analysts

Hold

Current Rating

30.000

Target Price

+1171.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-13

Its latest quarterly revenue reached 145.38K, representing a year-over-year decrease of 77.32%, while its net profit experienced a year-over-year decrease of 39.29%.

Score

Industry at a Glance

Previous score

5.96

Change



Financials

9.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.16

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Co-Diagnostics Inc's Company Valuation

Currency: USD Updated: 2026-01-13

The current valuation score of Co-Diagnostics Inc is 6.74, ranking 155 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -2.42, which is -92.86% below the recent high of -0.17 and -195.56% above the recent low of -7.16.

Score

Industry at a Glance

Previous score

6.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-13

The current earnings forecast score of Co-Diagnostics Inc is 7.00, ranking 150 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 1.25, with a high of 1.50 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Hold

Current Rating

30.000

Target Price

+1171.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Co-Diagnostics Inc

CODX

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-13

The current price momentum score of Co-Diagnostics Inc is 7.39, ranking 59 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 5.75 and the support level at -0.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.83

Change

-2.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.479

Buy

RSI(14)

48.630

Neutral

STOCH(KDJ)(9,3,3)

65.085

Sell

ATR(14)

0.908

High Vlolatility

CCI(14)

8.673

Neutral

Williams %R

64.518

Sell

TRIX(12,20)

19.309

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.336

Sell

MA10

4.403

Sell

MA20

2.328

Buy

MA50

1.151

Buy

MA100

0.770

Buy

MA200

0.533

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-13

The latest institutional shareholding proportion is 13.43%, representing a quarter-over-quarter increase of 4.41%. The largest institutional shareholder is The Vanguard, holding a total of 56.87K shares, representing 2.80% of shares outstanding, with 47.10% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ayrton Capital LLC

124.61K

The Vanguard Group, Inc.

Star Investors

56.87K

-1.58%

Orca Capital GmbH

62.86K

-14.04%

Private Advisory Group LLC

39.39K

Renaissance Technologies LLC

Star Investors

28.92K

+54.63%

Egan (Dwight H.)

28.73K

+15.21%

Abbott (Richard David)

23.22K

+6.01%

Brown (Brian Lee)

23.09K

+15.59%

BlackRock Institutional Trust Company, N.A.

14.25K

Serbin (Richard S)

10.97K

+21.17%

Risk Assessment

Currency: USD Updated: 2026-01-13

Co-Diagnostics Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.